BTLA and cancer: Our studies extend the current understanding about a distinct coinhibitory molecule expression pattern in CD4+ and CD8+ T cells, by showing distinct changes of BTLA and HVEM expressions on CD4+ and CD8+ T cell subset in human cancers.